

Special Issue

Alternatives to Antibiotics: Bacteriocins and Antimicrobial Peptides

Message from the Guest Editor

Dear Colleagues ☒

In recent years, the often indiscriminate use of antibiotics to control infectious diseases has led to an increase in multidrug antimicrobial resistance, causing serious problems in several fields. Therefore, this has become a critical issue for the discovery and development of new antimicrobial agents. Antimicrobial peptides and bacteriocins are some of the most promising candidates. Antimicrobial peptides are host defense peptides with a broad spectrum of activity, not only against bacteria, but also against fungi, parasites, and even enveloped viruses, and are less likely to induce resistance. Bacteriocins are bactericidal peptides produced by bacteria, that also exhibit antimicrobial activity with variable spectrum, depending on the peptide. Both these antimicrobial agents are already implemented in some areas, their true potential remains unlocked. This Special Issue is looking for manuscript submissions on all aspects of antibacterial peptides and bacteriocins, both old and new, and on how they can contribute to further benefiting human and veterinary health. Original research manuscripts, short communications, and reviews are welcomed.

Guest Editor

Dr. João Vilares Neves

Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal

Deadline for manuscript submissions

closed (28 February 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/68749

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)